FIGURE 4.
Changes in PROs in Asian patients by post-treatment week 12 with sofosbuvir-containing regimens (SVR-12 only). The PROs are normalized to a 0%–100% scale. Average across all 26 PROs: +1.2% (min −5.7%, max +8.8%) in RBV ± IFN (+SOF); +3.4% (min −13.1%, max +13.0%) in LDV/SOF.